A Phase II Study of MK0457 in Patients With T315I Mutant CML and Ph+All (0457-008)

Phase 2 Terminated 52 enrolled Merck Sharp & Dohme LLC

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study will evaluate MK0457 in patients with chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. Efficacy and safety will be evaluated.

Timeline

Start: 2006-12
Primary completion: 2009-06
Completion: 2009-06

Publications

Results Seymour JF, Kim DW, Rubin E, Haregewoin A, Clark J, Watson P, Hughes T, Dufva I, Jimenez JL, Mahon FX, Rousselot P, Cortes J, Martinelli G, Papayannidis C, Nagler A, Giles FJ. A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia. Blood Cancer J. 2014 Aug 15;4(8):e238. doi: 10.1038/bcj.2014.60.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	TOZASERTIB	Small molecule	24 mg/m2	Intravenous
Subject	TOZASERTIB	Small molecule	32 mg/m2	Intravenous
Subject	TOZASERTIB	Small molecule	40 mg/m2	Intravenous

A Phase II Study of MK0457 in Patients With T315I Mutant CML and Ph+All (0457-008)

Summary

Timeline

Publications

Drugs

Indications